Skip to main content

Abbott Laboratories Q3 FY2026 results

  • ABT · NYSE
  • Pharmaceuticals
  • Health Care Equipment
  • S&P 500
$108.52+1.18%Close 13 Nov 2026 · Market value $187.6B

Abbott Laboratories reported revenue of $13.0 billion, up 14.5% from a year earlier, net income of $920 million and diluted earnings per share of $0.53 against $0.94 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, filed 4 Nov 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.

Abbott Laboratories Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$13.01B$11.37B+14.5%
Gross profit$7.38B$6.29B+17.3%
Gross margin56.8%55.4%+1.4 pts
Operating income$1.36B$2.06B−34.0%
Operating margin10.4%18.1%−7.7 pts
Net income$920.0M$1.64B−44.0%
Diluted EPS$0.53$0.94−43.6%
Operating cash flow$1.74B$2.79B−37.7%
Capital expenditure$513.0M$496.0M+3.4%
Free cash flow$1.22B$2.29B−46.6%

Operating KPIs for the quarter

Abbott Laboratories operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Diabetes Care revenue$2.2Bup 6.2%
Core Laboratory revenue$1.4Bup 5.4%
Adult Nutritionals revenue$1.2Bup 2.0%
Key Emerging Markets revenue$1.2Bup 8.9%
Pediatric Nutritionals revenue$1.1Bup 8.8%
Cancer Diagnostics revenue$968.0M—
Rapid and Molecular revenue$899.0Mup 1.1%
Electrophysiology revenue$873.0Mup 14.9%
Vascular revenue$786.0Mup 5.5%
Rhythm Management revenue$752.0Mup 9.6%
Structural Heart revenue$592.0Mup 2.1%
Heart Failure revenue$387.0Mup 5.7%
Neuromodulation revenue$251.0Mdown 1.2%
Medical Devices revenue$5.8Bup 6.9%
Diagnostic Products revenue$3.3Bup 46.7%
Nutritional Products revenue$2.3Bup 5.1%
Established Pharmaceuticals revenue$1.6Bup 6.8%

Earlier quarters

Abbott Laboratories results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202630 Sep 2026$13.01B+14.5%$0.53
Q2 FY202630 Jun 2026$12.59B+13.0%$0.53
Q1 FY202631 Mar 2026$11.16B+7.8%$0.61
Q4 FY202531 Dec 2025$11.46B+4.4%$1.03
Q3 FY202530 Sep 2025$11.37B+6.9%$0.94
Q2 FY202530 Jun 2025$11.14B+7.4%$1.01
Q1 FY202531 Mar 2025$10.36B+4.0%$0.76
Q4 FY202431 Dec 2024$10.97B+7.2%$5.28

More on Abbott Laboratories: financial statements · revenue · earnings per share

ABT's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.